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Mutant RAS-driven tumorigenesis was thought for decades to arise independently of wild-type RAS
isoforms, but recent evidence indicates wild-type isoforms are involved. In this issue of Cancer Cell, Gra-
bocka and colleagues report how the loss of wild-type RAS alters oncogenic signaling and dampens the
DNA-damage response, thereby affecting tumor progression and chemosensitivity.It has been more than 30 years since
constitutively active mutant forms of
KRAS, HRAS, and NRAS were shown to
transform cells in culture, thus suggesting
their ability to drive tumorigenesis autono-
mously. Indeed, it is now known that
mutations in these genes contribute to
loss of growth control in approximately
30% of all human cancers (Pylayeva-
Gupta et al., 2011). However, detailed
analyses of the growth factor signaling
pathways impacted by RAS later demon-
strated that wild-type (WT) RAS isoforms
play a significant role in the transformative
abilities of oncogenic RAS mutants
(Huang et al., 1993; Lim et al., 2008;
Young et al., 2013), but the molecular
mechanism remained unknown. In this
issue of Cancer Cell, Grabocka et al.
(2014) provide a major advance in under-
standing the relationship between onco-
genic RAS and WT RAS isoforms in
tumorigenesis by elucidating how ex-
pression of WT RAS isoforms affect both
tumor progression and chemotherapeutic
sensitivity by modulating the DNA dam-
age response.
To examine the contribution of WT RAS
isoforms in promoting tumorigenesis in
KRAS-driven tumors, Grabocka et al.
(2014) first use WT KRAS and mutant
KRAS (G12D) pancreatic and colon
carcinoma cells engineered for inducible
suppression of WT HRAS and NRAS
expression. They show that silencing of
HRAS or NRAS in mutant-KRAS cells
increases MAPK-RSK and PI3K-AKT
signaling and delays progression through
G2/M phase, but has no effect on cells
expressing WT KRAS. Furthermore, no
substantial change in this delay was
observed when both HRAS and NRAS
were concurrently depleted, suggesting
that HRAS and NRAS function within asingle module to regulate oncogenic
KRAS signaling. Together with previous
studies, these results demonstrate that
HRAS and NRAS work to limit oncogenic
signaling, which, in turn, leads to cell cycle
delays.
The delayed cell cycle progression and
mitotic defects observed upon WT RAS
isoform suppression are consistent with
the well-established effect of oncogenic
signaling on genomic instability and cell
cycle checkpoint activation. Oncogenic
RAS expression, like most oncogenes,
causes replication stress, which is
defined as the DNA damage response
(DDR) associated with perturbed S phase
progression, and leads to the activation of
the ATR and ATM kinases (Halazonetis
et al., 2008). Engagement of the DDR
initially acts as a barrier to tumorigenesis
by inducing cell cycle arrest, senescence,
or apoptosis. However, as tumors evolve,
attenuation or loss of specific compo-
nents of the DDR, such as p53, sup-
presses these outcomes, thus affording
tumor progression. CHK1, a checkpoint
kinase operating directly downstream of
ATR, has been shown in some cases to
be inhibited by growth factor signaling
pathways through phosphorylation on
S280, which prevents CHK1 activation
via phosphorylation of S317 and S345
by ATR (King et al., 2004). Therefore,
S280 phosphorylation of CHK1 is one
mechanism among many by which the
oncogenic stress-induced checkpoint
response can be compromised. However,
checkpoint abrogation can be a double-
edged sword, allowing cell cycle progres-
sion but further promoting genomic
instability.
Grabocka et al. (2014) demonstrate that
depletion of HRAS or NRAS leads to an
increase in inhibitory phosphorylation ofCancer Cell 25,CHK1 at S280 and a decrease of
phospho-CHK1 at S317 and S345without
affecting the ATM-CHK2 signaling
pathway. Consistent with checkpoint
mitigation after suppression of WT RAS
isoforms, KRAS mutant cells failed to
block mitotic entry soon after exogenous
DNA damage. Because the long-term
effects of checkpoint abrogation can be
genome destabilizing, these results are
in agreement with the observed mitotic
defects and increased phosphorylation
of the histone variant H2AX (gH2AX)
when WT RAS isoforms were suppressed
in mutant RAS-transformed cells. These
findings indicate that oncogene-enforced
limitation of DNA damage checkpoint
control may promote additional genomic
instability in affected tumors (Figure 1).
Although the analysis described above
goes far to explain the mechanism of cell
cycle perturbations through CHK1 inhibi-
tion, it raises important questions about
the mechanism by which WT RAS iso-
forms promote CHK1 S280 phosphoryla-
tion. Previous reports have shown that
both the MAPK-RSK and PI3K-AKT path-
ways can cause CHK1 S280 phosphory-
lation (King et al., 2004; Ray-David et al.,
2013). Grabocka et al. (2014) demonstrate
that both of these pathways, MAPK-RSK
and PI3K-AKT, are activated and involved
in S280 phosphorylation upon suppres-
sion of WT RAS isoforms in KRASG12D-
expressing cells, and that each pathway
contributes to CHK1 S280 phosphoryla-
tion. Similar to cultured cells, depletion
of WT HRAS in mutant KRAS tumor xeno-
grafts also resulted in hyperactivation of
the MAPK-RSK and PI3K-AKT pathways
as well as repression of CHK1 activity
following exposure to DNA-damaging
chemotherapeutic agents. Thus, the
silencing of WT HRAS and NRAS inFebruary 10, 2014 ª2014 Elsevier Inc. 137
Figure 1. Regulation of the DNA Damage Response byWild-Type RAS in Mutant KRAS Cells
WT RAS antagonizes mutant KRAS signaling, thereby limiting the inhibitory phosphorylation of CHK1 at
S280 from MAPK-RSK and PI3K-AKT signaling. Uninhibited pools of CHK1 afford an active DNA damage
checkpoint response and some degree of genome maintenance. Suppressing WT RAS hyperactivates
mutant KRAS signaling, which increases inhibitory phosphorylation of CHK1 at S280. CHK1 inhibition
dampens the checkpoint and increases genomic instability.
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Previewsmutant KRAS cells leads to CHK1 S280
phosphorylation through hyperactivation
of both the MAPK-RSK and PI3K-AKT
pathways (Figure 1).
Mutation or deletion of p53 is well
known to confer a survival advantage to
cancer cells by hampering induction of
apoptosis from DNA-damaging chemo-
therapy; however, the opposite effect is
observed in response to DNA-damaging
agentswhenmostother checkpoint genes
are compromised. Indeed, genomic insta-
bility is exacerbated by checkpoint failure
when cells with damaged DNA enter
mitosis. With this feature of checkpoint
failure in mind, the authors then queried
whether cells with dampened checkpoint
activity due to CHK1 S280 phosphoryla-
tion would be particularly sensitive to
DNA damaging chemotherapies. They
found that combining knockdown of WT
HRAS with irinotecan caused an increase
in cell death and tumor regression
compared to either treatment alone.
Because suppression ofWTRAS isoforms
sensitized tumors to a standard DNA-
damaging treatment, these results may
have significant value in the design of
novel combinatorial treatments for mutant138 Cancer Cell 25, February 10, 2014 ª2014KRAS-associated cancers. In summary,
Grabocka et al. (2014) have now demon-
strated that silencing of WT HRAS or
NRAS in mutant KRAS cells significantly
influences cancer biology in a way that
will facilitate the design of individualized
treatments.
Although the authors’ findings increase
our mechanistic understanding of how
WT and mutant RAS isoforms interact to
promote tumor progression andmodulate
responses to DNA-damaging chemother-
apies, interesting questions remain.
For example, the effect of the WT KRAS
allele on mutant KRAS-driven tumorigen-
esis and DDR signaling has not yet been
determined. This research area is
relevant given that the WT KRAS allele is
often downregulated or completely lost
in mutant KRAS-driven cancer cells.
Because recent findings suggest both
tumor-suppressive and promoting roles
for expression of the WT KRAS allele
(Zhang et al., 2001; Matallanas et al.,
2011), it is not immediately apparent
how expression of the WT KRAS allele
will affect oncogenic KRAS-transformed
cells. Furthermore, it is important to note
that oncogenic RAS has been associatedElsevier Inc.with increased, not decreased, CHK1
activity (Halazonetis et al., 2008; Gilad
et al., 2010). In these cases, CHK1 activity
may be slightly stimulated by oncogenic
stress, but only to suboptimal levels that
are insufficient to counter the frequency
of replication abnormalities produced
by oncogene expression, leading to
increased replication fork collapse and
genomic instability (Gilad et al., 2010).
Therefore, these studies predict great
potential for ATR and CHK1 inhibitors as
treatments for KRAS-driven cancers
through their ability to further reduce
ATR-CHK1 signaling to levels that are
toxic (Gilad et al., 2010). Clearly, Gra-
bocka et al. (2014) have provided novel
insight into the role of WT RAS isoforms
in regulating the DDR, providing a fresh
look at a long-standing research question
that will undoubtedly stimulate new dis-
coveries for decades to come.REFERENCES
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